New pill takes on tough lung cancer mutation

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Voluntary participation in the study and signed informed consent form (ICF). * 2\. Age ≥ 18 years at the time of signing the ICF; male or female. * 3\. Histologically or cytologically confirmed locally advanced unresectable or metastatic non small cell lung cancer (NSCLC). * 4\. Participants must provide adequate and qualified tumor tissue slides samples or agree to undergo tumor biopsy to obtain tissue samples for central laboratory confirmation of KRAS G12D mutation. * 5\. Disease progression or intolerance to toxicity after at least one prior line of platinum based chemotherapy and anti PD 1/PD L1 antibody therapy. * 6\. At least one measurable target lesion according to RECIST version 1.1. * 7\. Investigator assessed life expectancy ≥ 12 weeks. * 8\. Adequate organ function. * 9\. Ability to communicate well, comply with scheduled follow up visits, and adhere to protocol requirements. Exclusion Criteria: * 1\. Presence of other driver gene mutations in NSCLC, or concurrent other KRAS or RAS mutations. * 2\. Other malignancy that has progressed or required treatment within 3 years prior to randomization. * 3\. Leptomeningeal metastasis, or symptomatic or progressive central nervous system (CNS) metastasis. * 4\. Existing or potential severe bone injury due to bone metastasis, or uncontrolled pain related to bone metastasis. * 5\. Prior treatment with KRAS G12D targeted therapy or pan RAS/KRAS targeted therapy. * 6\. Prior treatment with docetaxel as part of systemic therapy. * 7\. Radiotherapy within 4 weeks prior to randomization, or other local anti tumor therapy within 4 weeks prior to randomization. * 8\. Other anti tumor therapy within 28 days or 5 half lives prior to randomization, or cell therapy within 3 months prior to randomization. * 9\. Clinically significant severe cardiovascular disease. * 10\. Stroke or other severe cerebrovascular disease within 6 months prior to randomization. * 11\. Major acute or chronic infectious disease. * 12\. Other poorly controlled systemic diseases. * 13\. Severe psychiatric or psychological disorder, or history of drug abuse, or severe alcohol abuse. * 14\. Pregnancy or breastfeeding. * 15\. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.